

CONTINUED PROSECUTION APPLICATION (CPA) REQUEST TRANSMITTAL

Submit an original, and a duplicate for fee processing
(Only for Continuation or Divisional applications under 37 CFR 1.53(d))

☐ DUPLICATE

Address to:

**Assistant Commissioner of Patents
Box CPA
Washington, DC 20231**

Attorney Docket No. MARGI 15

First Inventor Angela TURIANO

Group Art Unit 1642

Examiner G. Bansal

This is a request for a ☒ continuation or ☐ divisional application under 37 CFR 1.53(d)
(continued prosecution application (CPA)) of prior application number 08/817,595
filed on April 22, 1997 entitled PHARMACEUTICAL COMPOSITION FOR STIMULATION OF THE IMMUNE SYSTEM

1. ☐ Enter the unentered amendment previously filed under 37 CFR 1.116 in the prior nonprovisional application.
2. ☐ A preliminary amendment is enclosed.
3. ☐ This application is filed by fewer than all the inventors named in the prior application, 37 CFR 1.53 (d)(4)
 - a. ☐ DELETE the following inventor(s) named in the prior nonprovisional application:
 - b. ☐ The inventor(s) to be deleted are set forth on a separate sheet attached hereto.
4. ☐ A new power of attorney or authorization of agent (PTO/SB/81) is enclosed.
5. Information Disclosure Statement (IDS) is enclosed:
 - a. ☐ PTO-1449
 - b. ☐ Copies of IDS Citations

RECEIVED

DEC 08 2000

TECH CENTER 1600/2900

CLAIMS	NUMBER FILED		NUMBER EXTRA	RATE	CALCULATIONS
TOTAL	15	MINUS 20	0	× \$18 =	\$0.00
INDEPENDENT	2	MINUS 3	0	× \$80 =	\$0.00
		<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS		+ \$270 =	\$0.00
		BASIC FEE			\$710.00
		TOTAL OF ABOVE CALCULATIONS			\$710.00
		<input type="checkbox"/> Reduction by 50% for filing by Small Entity			\$0.00
		TOTAL			\$710.00

6. Small Entity Status:

- a. ☐ A small entity statement is enclosed.
- b. ☐ A small entity statement was filed in the prior nonprovisional application and such status is still proper and desired.
- c. ☐ Is no longer claimed.
7. ☒ The Commissioner is hereby authorized to charge fees under 37 CFR 1.16 and 1.17 for the papers being filed herewith and for which no check is enclosed, or credit any overpayment to Deposit Account No. **13-3402**.
☒ If these papers are not considered timely filed by the Patent and Trademark Office, then a petition is hereby made under 37 CFR 1.136 for the necessary extension of time in the parent case. Any fees required for such an extension of time may be charged to Deposit Account No. **13-3402**.
8. ☒ A check in the amount of **\$710.00** is enclosed.
9. ☐ Other:

12/06/2000 CNGUYEN 00000042 08817595

01 FC:131

710.00 OP

Respectfully submitted,

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.

2200 Clarendon Blvd., Suite 1400
Arlington, VA 22201
Tel. (703) 243-6333
Fax (703) 243-6410

Anthony J. Zefano
Registration No. 27,969


Nancy J. Axelrod
Registration No. 44,014

filed December 5, 2000

K:\PAT\margi\15\cpa 12-5-00.wpd
AJZ/NJA/lvb:

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

In re application of :
Angela TURIANO : Group Art Unit: 1642
Serial No. 08/817,595 : Examiner: G. Bansal
Filed: April 22, 1997 :



For: PHARMACEUTICAL COMPOSITION FOR STIMULATION OF THE IMMUNE SYSTEM

REPLY

RECEIVED

Assistant Commissioner for Patents
Washington, D.C. 20231

DEC 08 2000

SIR:

TECH CENTER 1600/2900

In response to the Office Action dated January 4, 2000, please amend the above-identified application as indicated below and consider the remarks which follow:

IN THE CLAIMS:

Please cancel claims 10-24 without prejudice or disclaimer

Please add the following claims:

---25. A kit (useful for the treatment of cancer in a patient), comprising at least two containers, each comprising an extract from an animal tissue, serum or cell source different from that of the other container,
wherein said extracts comprise MHC molecules and associated molecules;
are preparable by a) homogenizing the tissue, serum or cell source in the presence of NP40, or b) treating said source with an acid, or c) treating said source with a proteolytic enzyme; and

allergenic and/or xenogenic to the patient